Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.

Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, Spratt DE, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R.

Eur Urol. 2018 Jul 3. pii: S0302-2838(18)30444-5. doi: 10.1016/j.eururo.2018.06.019. [Epub ahead of print] No abstract available.

PMID:
29980330
2.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
3.

Surgical Approach to Bone Metastases.

Siegel GW, Biermann JS, Calinescu AA, Spratt DE, Szerlip NJ.

Curr Osteoporos Rep. 2018 Jun 18. doi: 10.1007/s11914-018-0463-7. [Epub ahead of print] Review.

PMID:
29915966
4.

Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.

Spratt DE, Schaeffer EM.

Eur Urol. 2018 Jun 12. pii: S0302-2838(18)30426-3. doi: 10.1016/j.eururo.2018.06.001. [Epub ahead of print] No abstract available.

PMID:
29907357
5.

Mentorship Experiences of Early-Career Academic Radiation Oncologists in North America.

Lalani N, Griffith KA, Jones RD, Spratt DE, Croke J, Jagsi R.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):732-740. doi: 10.1016/j.ijrobp.2018.03.035. Epub 2018 Mar 30.

PMID:
29893281
6.

Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.

Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):513-515. doi: 10.1016/j.ijrobp.2018.03.008. No abstract available.

PMID:
29893267
7.

The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.

Raman S, Moraes FY, Mendez LC, Taunk NK, Suh JH, Souhami L, Slotman B, Kongkham P, Spratt DE, Berlin A, Marta GN.

J Neurooncol. 2018 Aug;139(1):195-203. doi: 10.1007/s11060-018-2860-2. Epub 2018 Jun 4.

PMID:
29869023
8.

Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?

Spratt DE, Carroll PR.

J Clin Oncol. 2018 May 21:JCO2018786236. doi: 10.1200/JCO.2018.78.6236. [Epub ahead of print] No abstract available.

PMID:
29782208
9.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 May 14. doi: 10.1158/1078-0432.CCR-17-2745. [Epub ahead of print]

PMID:
29760221
10.

Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis.

Spratt DE, Mancini BR, Hayman JA, Boike T, Pierce LJ, Moran JM, Dominello MM, Fireman M, Griffith K, Jolly S; Michigan Radiation Oncology Quality Consortium.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):462-467. doi: 10.1016/j.ijrobp.2018.02.037. Epub 2018 Mar 6.

PMID:
29726364
11.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

PMID:
29509865
12.

Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.

Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):376-386. doi: 10.1016/j.ijrobp.2018.01.055. Epub 2018 Jan 31.

PMID:
29487023
13.

Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning.

Younge KC, Marsh RB, Owen D, Geng H, Xiao Y, Spratt DE, Foy J, Suresh K, Wu QJ, Yin FF, Ryu S, Matuszak MM.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1067-1074. doi: 10.1016/j.ijrobp.2017.12.276. Epub 2018 Jan 4.

PMID:
29485048
14.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

PMID:
29478736
15.

Changes in prostate orientation due to removal of a Foley catheter.

Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JW, Schipper MJ, Spratt DE.

Med Phys. 2018 Apr;45(4):1369-1378. doi: 10.1002/mp.12830. Epub 2018 Mar 25.

PMID:
29474748
16.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
17.

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.

Spratt DE, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, Palapattu GS, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R.

Med Oncol. 2018 Jan 31;35(3):21. doi: 10.1007/s12032-018-1090-y.

PMID:
29387987
18.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10.

PMID:
29372236
19.

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.

Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31070-9. doi: 10.1016/j.eururo.2017.12.023. [Epub ahead of print]

PMID:
29306514
20.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
21.

Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.

Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL.

Ann Oncol. 2018 Feb 1;29(2):386-391. doi: 10.1093/annonc/mdx744.

PMID:
29267861
22.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
23.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL.

Cancer. 2018 Mar 15;124(6):1141-1149. doi: 10.1002/cncr.31190. Epub 2017 Dec 12.

PMID:
29231964
24.

An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report.

Spratt DE, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ, Younge KC, Bilsky M, Park P, Szerlip NJ.

Lancet Oncol. 2017 Dec;18(12):e720-e730. doi: 10.1016/S1470-2045(17)30612-5. Review.

PMID:
29208438
25.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
26.

Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials.

Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, Souhami L, Slotman B, Weltman E, Spratt DE, Berlin A, Marta GN.

J Neurooncol. 2018 Feb;136(3):585-593. doi: 10.1007/s11060-017-2687-2. Epub 2017 Nov 21.

PMID:
29164521
27.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
29.

Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature.

Smith BW, Joseph JR, Saadeh YS, La Marca F, Szerlip NJ, Schermerhorn TC, Spratt DE, Younge KC, Park P.

World Neurosurg. 2018 Jan;109:e502-e509. doi: 10.1016/j.wneu.2017.10.011. Epub 2017 Oct 13. Review.

PMID:
29038086
30.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Dec;77(16):1592-1600. doi: 10.1002/pros.23436. Epub 2017 Oct 10.

PMID:
28994485
31.

Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study.

Udager AM, McHugh JB, Morgan TM, Spratt DE, Chinnaiyan AM, Mehra R.

Appl Immunohistochem Mol Morphol. 2017 Sep 29. doi: 10.1097/PAI.0000000000000597. [Epub ahead of print]

PMID:
28968266
32.

Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.

Shen J, Wang L, Daignault S, Spratt DE, Morgan TM, Taylor JMG.

J Biopharm Stat. 2018;28(2):362-381. doi: 10.1080/10543406.2017.1380036. Epub 2017 Oct 25.

PMID:
28934002
33.

Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Nov;77(15):1478-1488. doi: 10.1002/pros.23424. Epub 2017 Sep 18. Review.

PMID:
28925066
34.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
35.

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.

Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.

NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.

36.

Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.

Green M, Feng FY, Mehra R, Spratt DE.

Immunotherapy. 2017 Aug;9(9):695-699. doi: 10.2217/imt-2017-0059. Epub 2017 Aug 3. No abstract available.

37.

Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.

Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R.

Eur Urol Focus. 2017 Oct;3(4-5):502-509. doi: 10.1016/j.euf.2016.11.011. Epub 2016 Dec 13.

PMID:
28753826
38.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF Rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2017 Jun 17. pii: S2405-4569(17)30148-7. doi: 10.1016/j.euf.2017.05.011. [Epub ahead of print]

PMID:
28753811
39.

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer.

Gadia R, Teixeira Leite ET, Bierrenbach AL, Ynoe de Moraes F, Spratt DE, Arruda FF, Cintra Vita Abreu CE, Fernandes da Silva JL, de Andrade Carvalho H, Garicochea B.

Adv Radiat Oncol. 2016 Oct 29;1(4):300-309. doi: 10.1016/j.adro.2016.10.006. eCollection 2016 Oct-Dec.

40.

Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes.

Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL.

Eur Urol Focus. 2016 Dec;2(5):532-539. doi: 10.1016/j.euf.2016.03.010. Epub 2016 Apr 1.

PMID:
28723519
41.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.

Eur Urol. 2018 Feb;73(2):156-165. doi: 10.1016/j.eururo.2017.06.027. Epub 2017 Jul 14. Review.

PMID:
28716370
42.

Erectile function after stereotactic body radiotherapy for localized prostate cancer.

Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE.

BJU Int. 2018 Jan;121(1):61-68. doi: 10.1111/bju.13962. Epub 2017 Aug 17.

PMID:
28710895
43.

Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):952. doi: 10.1007/s11307-017-1104-8. No abstract available.

PMID:
28695370
44.

Performance and Utility of Prognostic Genomic Biomarkers After Prostatectomy: Decipher-ing the Data.

Spratt DE.

J Clin Oncol. 2017 Sep 1;35(25):2977-2978. doi: 10.1200/JCO.2017.73.6470. Epub 2017 Jul 6. No abstract available.

PMID:
28682686
45.

Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, Spratt DE.

Curr Urol Rep. 2017 Jul;18(7):55. doi: 10.1007/s11934-017-0700-0. Review.

PMID:
28589403
46.

Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.

Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB.

BJU Int. 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5.

PMID:
28581200
47.

Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy.

Wang ML, McHugh JB, Weizer AZ, Morgan TM, Chinnaiyan AM, Sciallis AP, Lagstein A, Spratt DE, Mehra R.

Urol Case Rep. 2017 May 23;13:154-157. doi: 10.1016/j.eucr.2017.04.014. eCollection 2017 Jul.

48.

Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):944-951. doi: 10.1007/s11307-017-1091-9. Erratum in: Mol Imaging Biol. 2017 Jul 10;:.

49.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Urol Oncol. 2017 Sep;35(9):542.e25-542.e32. doi: 10.1016/j.urolonc.2017.04.018. Epub 2017 May 19.

PMID:
28533151
50.

Convergence of Genomic Instability and SChLAP1: Weathering the Storm of Intraductal Carcinoma of the Prostate.

Spratt DE.

Eur Urol. 2017 Nov;72(5):675-676. doi: 10.1016/j.eururo.2017.05.015. Epub 2017 May 18. No abstract available.

PMID:
28528812

Supplemental Content

Loading ...
Support Center